Pharmaceuticals

Viral Vectors And Plasmid DNA Market Forecast Showing Industry Progress And Growth Trends

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Level Of Market Value Growth Is Predicted For The Viral Vectors And Plasmid DNA Market From 2026 To 2030?

The market for viral vectors and plasmid DNA has seen substantial expansion over recent years. Projections indicate it will rise from $1.38 billion in 2025 to $1.47 billion by 2026, achieving a compound annual growth rate (CAGR) of 6.2%. The market’s past expansion is traceable to several factors, including the constrained supply of viral vectors, dependence on research-grade plasmid DNA, the proliferation of gene therapy pipelines, heightened biopharmaceutical R&D efforts, and the utilization of conventional viral vector platforms.

The viral vectors and plasmid dna market size is projected to experience substantial expansion in the coming years. By 2030, this market is anticipated to reach $1.89 billion, showing a compound annual growth rate (CAGR) of 6.6%. Several factors will drive this growth during the projection period, including the advancement of clinical-grade and GMP plasmid DNA, the broader use of viral vector applications in cancer and infectious diseases, increased funding in gene therapy, a greater need for immunotherapy solutions, and the incorporation of novel vector platforms such as AAV and lentiviral vectors. Key trends expected during this forecast timeframe encompass the increasing utilization of plasmid DNA and viral vectors in gene therapy, the broadened scope of viral vector platforms for addressing cancer and genetic disorder treatments, an uptick in GMP-grade plasmid DNA production for clinical applications, intensified research into novel adeno-associated and lentiviral vectors, and the integration of plasmid DNA and viral vectors into immunotherapy and vaccine development.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3245&type=smp

What Key Drivers Are Fueling The Growth Of The Viral Vectors And Plasmid DNA Market?

The rising prevalence of tuberculosis cases is anticipated to drive forward the growth of the viral vector and plasmid DNA market. Tuberculosis (TB) is a transmissible and potentially severe infectious illness caused by bacteria, primarily impacting the lungs but capable of affecting other body parts. Plasmid DNA vaccines have been employed to introduce microbial antigen-coding genes for tuberculosis. These vaccines can be engineered to express specific antigens of Mycobacterium tuberculosis, the bacterium responsible for TB, and are administered via intramuscular injection. For instance, in February 2024, GOV.UK, a UK-based government department, disclosed that tuberculosis (TB) cases in England increased by 10.7% in 2023, climbing from 4,380 in 2022 to 4,850. Consequently, the increasing occurrence of tuberculosis cases is propelling the growth of the viral vector and plasmid DNA market.

How Is The Viral Vectors And Plasmid DNA Market Segmented Across Different Segment Categories?

The viral vectors and plasmid dna market covered in this report is segmented –

1) By Product: Plasmid DNA, Viral Vectors

2) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Other Diseases

3) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications

4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies

Subsegments:

1) By Plasmid DNA: Research-Grade Plasmid DNA, Clinical-Grade Plasmid DNA, GMP (Good Manufacturing Practice) Plasmid DNA

2) By Viral Vectors: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Vesicular Stomatitis Virus (VSV) Vectors

What Trends Are Affecting The Direction Of The Viral Vectors And Plasmid DNA Market?

Major companies operating in the viral vectors and plasmid DNA market are increasingly focusing on launching innovative products, such as helper plasmids, to gain a market advantage. A helper plasmid is a specific type of plasmid DNA integral to the production of viral vectors, including adeno-associated viral vectors (AAV), which are commonly employed in gene therapy. Illustratively, in March 2023, Charles River Laboratories International Inc., a US-based pharmaceutical company, unveiled off-the-shelf pHelper. This helper plasmid aims to expedite the journey of adeno-associated virus (AAV)-based gene therapy programs from early research stages through to commercial manufacturing, concurrently securing necessary supplies. As a new offering among a wide array of contract development and manufacturing organization (CDMO) goods and services, these helper plasmids are designed to protect viral vector packaging in cell and gene therapy operations, streamline complex supply chains, and facilitate the creation of adeno-associated viral vectors (AAV) that are frequently utilized in gene therapy.

Which Organizations Play A Role In The Viral Vectors And Plasmid DNA Market Landscape?

Major companies operating in the viral vectors and plasmid dna market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza Group AG, Cobra Biologics and Pharmaceutical Services, Brammer Bio, ??n?k? ??r??r?t??n, Cell and Gene Therapy Catapult, VGXI Inc., MassBiologics, Sanofi, Spark Therapeutics, UniQure NV, Thermo Fisher Scientific, VIROVEK, SIRION Biotech GmbH, ALDEVRON, Oxford BioMedica, PlasmidFactory GmbH & Co. KG, Biovian Oy, BioReliance Corporation, 4D Molecular Therapeutics, Renova Therapeutics, Shenzhen SiBiono GeneTech Co., Vigene Biosciences Inc., Novasep, Genzyme Corporation, Oxford Gene Technology, Richter-Helm, MolMed, Merck KGaA Inc., Catalent Inc., WuXi AppTec, GenScript Biotech Corporation, Eurogentec, Creative Biogene

Get The Full Viral Vectors And Plasmid DNA Market Report:

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

Where Is The Viral Vectors And Plasmid DNA Market Primarily Concentrated By Region?

North America was the largest region in the viral vectors and plasmid DNA market in 2025. The Middle East is expected to be the fastest-growing region in the global viral vectors & plasmid DNA market analysis. The regions covered in the viral vectors and plasmid dna market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Viral Vectors And Plasmid DNA Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report

Browse Through More Reports Similar to the Global Viral Vectors And Plasmid DNA Market 2026, By The Business Research Company

Anti Infective Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/anti-infective-drugs-market

Antivirals Market Report 2026

https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report

Hospital Acquired Infections Testing Kits Market Report 2026

https://www.thebusinessresearchcompany.com/report/hospital-acquired-infections-testing-kits-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795